<DOC>
	<DOCNO>NCT01839968</DOCNO>
	<brief_summary>The purpose ex-vivo study estimate optimal platelet quantity necessary reverse antiplatelet effect prasugrel .</brief_summary>
	<brief_title>Ex-Vivo Reversion Platelet Inhibition Induced Prasugrel</brief_title>
	<detailed_description />
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Acute coronary syndrome Prasugrel load dose 624h inclusion Clopidogrel load dose GPIIbIIIa use within 10 day inclusion Known congenital thrombopathy and/or congenital coagulation defect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>